

Tackling gender in progressive supranuclear palsy: Male patients present more apathy

Journal of Parkinson's Disease
2025, Vol. 15(5) 1024–1028
© The Author(s) 2025
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1877718X251343094
journals.sagepub.com/home/pkn



Lan Ye¹ , Stephan Greten¹ , Ida Wilkens^{1,2} , Florian Wegner¹ , Lea Krey¹ , Matthias Höllerhage¹ , Monika Pötter-Nerger³ , Molly Zeitzschel³ , Keno Hagen³ , Jan Kassubek^{4,5} , Patrick Süß^{6,7} , Jürgen Winkler^{6,7} , Daniela Berg⁸ , Steffen Paschen⁸ , Lars Tönges^{9,10} , Doreen Gruber^{11,12} , Florin Gandor^{11,12} , Wolfgang H Jost¹³ , Andrea A Kühn^{14,15} , Inga Claus¹⁶ , Tobias Warnecke¹⁷ , David J Pedrosa¹⁸ , Carsten Eggers¹⁹ , Claudia Trenkwalder²⁰ , Joseph Classen²¹ , Johannes Schwarz²² , Alfons Schnitzler²³ , Günter U Höglinger^{2,24,#} and Martin Klietz^{1,#}

Abstract

Gender differences in progressive supranuclear palsy (PSP) may become relevant for clinical trials, treatment decisions and patient counseling. To study gender associated differences we conducted a retrospective data analysis of 191 male and 157 female PSP patients from a large multicenter observational cohort in Germany. While no differences in motor skills, disease severity, daily living abilities, global cognitive status and depressive symptoms were observed between genders, male patients showed significantly higher apathy scores, a finding also noted in other neurological diseases. In this study, apart from male patients exhibiting higher levels of apathy, no significant disease-specific gender differences were observed in PSP patients.

¹Department of Neurology, Hannover Medical School, Hannover, Germany

²Department of Neurology, LMU University Hospital, Munich, Germany

³Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

⁴Department of Neurology, University of Ulm, Ulm, Germany

⁵German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany

⁶Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

⁷Center of Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

⁸Department of Neurology, Kiel University, Kiel, Germany

⁹Department of Neurology, St Josef-Hospital, Ruhr University Bochum, Bochum, Germany

¹⁰Neurodegeneration Research, Protein Research Unit Ruhr (PURE), Ruhr University Bochum, Bochum, Germany

¹¹Movement Disorders Hospital, Beelitz-Heilstätten, Germany

¹²Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

¹³Parkinson-Klinik Ortenau, Wolfach, Germany

¹⁴Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Berlin, Germany

¹⁵German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

¹⁶Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, Muenster, Germany

¹⁷Department of Neurology and Neurorehabilitation, Klinikum Osnabrueck - Academic teaching hospital of the WWU Muenster, Osnabrueck, Germany

¹⁸Department of Neurology, University Hospital of Marburg, Marburg, Germany

¹⁹Department of Neurology, Knappschafts-Krankenhaus Bottrop, Bottrop, Germany

²⁰Department of Neurology, Paracelsus-Elena Klinik, Kassel, Germany

²¹Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany

²²Department of Neurology, Kreilklinik Ebersberg, Ebersberg, Germany

²³Institute of Clinical Neuroscience and Medical Psychology, and Department of Neurology, University of Düsseldorf, Düsseldorf, Germany

²⁴Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany

[#]These authors contributed equally to this work.

Corresponding author:

Lan Ye, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Email: Ye.Lan@mh-hannover.de



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

Plain language summary: This study investigated whether there are any differences between men and women with a rare brain disorder called progressive supranuclear palsy (PSP). By damaging certain areas of the brain, it can cause progressive problems with balance, movement, vision, speech and swallowing. It can also affect mood, behavior, and thinking abilities. We analyzed data from 191 men and 157 women with PSP who were part of a large study in Germany. It turned out that men and women had similar abilities in movement, daily activities, overall mental ability, and mood (specifically depressive symptoms). However, among people with PSP, men showed higher levels of apathy - a lack of feeling, emotion, interest, or concern about something - than women. Such phenomenon has also been observed in patients with other brain disorders. Overall, this study found no significant gender differences between men and women in PSP, suggesting that gender may not play a major role in the progression of PSP.

Keywords

progressive supranuclear palsy, gender, apathy

Received: 12 November 2024; accepted: 13 April 2025

Introduction

Gender is a multidimensional concept influenced by social, cultural, and behavioral factors and may modulate health.¹ Gender differences in neurodegenerative diseases are drawing increased attention. Progressive supranuclear palsy (PSP) is a neurodegenerative disorder encompassing a spectrum of clinical phenotypes involving parkinsonism, early postural instability and falls, vertical supranuclear gaze palsy, pseudobulbar symptoms, and cognitive decline.² There were only a handful of studies on gender differences in PSP,^{3–6} and the impact of gender-related factors on PSP are not well established yet. An enhanced understanding of the gender differences is crucial for improvements in diagnosis, treatment as well as clinical trial research in PSP.

Methods

In this study, we retrospectively investigated gender differences in patients from a prospective multicenter observational cohort ($n=348$) in Germany. The PSP diagnosis was determined by a movement disorder specialist according to the Movement Disorders Society diagnostic criteria for PSP.⁷ The demographic information was collected, including gender, age at disease onset, age at baseline, height and bodyweight. To comprehensively evaluate cognitive functions, motor skills, quality of life and depressed mood in PSP patients, various scales were used. The Montreal Cognitive Assessment (MoCA) was applied to assess global cognitive status, while the Luria Sequence and Three Claps Test evaluated executive functions and motor control. Disease severity was monitored using the Progressive Supranuclear Palsy Rating Scale (PSPRS). Daily living abilities and clinical deficits were evaluated through the PSP Quality of Life Scale (PSP-QoL) and Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS).⁸ The Starkstein Apathy Scale (SSAS)

measured levels of apathy, and the Geriatric Depression Scale-15 items (GDS-15) was used to detect depressive symptoms. To compare clinical progression over one-year the annualized progression was calculated for each patient according to other studies of our group.^{8,9}

Results

In total, this study examined 191 men and 157 women diagnosed with PSP at baseline. A follow-up examination was carried out 52 weeks after the baseline evaluation including 81 men and 70 women. Men and women with PSP exhibited similar ages of disease onset and ages at baseline.

Out of all patients, specific PSP phenotypes were documented for 241 patients. The distribution of different phenotypes of PSP showed slightly more male patients with the diagnosis of PSP-P, which did not reach statistical significance (Table 1, $n=241$, Fisher test, $p>0.05$).

Demographic data and outcome variables at baseline and one-year follow up are displayed in Table 2. Both men and women showed a significant increase in disease severity over 52 weeks with increased PSPRS scores (men: baseline vs. 52 weeks: 34.3 ± 14.8 vs. 42.2 ± 16.4 , Mann-Whitney U test, $p<0.05$; women: baseline vs. 52 weeks 36.2 ± 15.2 vs. 42.1 ± 18.7 Mann-Whitney U test, $p<0.05$). However, there was no significant difference between both genders in the PSPRS over one year (men vs. women at baseline: 34.3 ± 14.8 vs. 36.2 ± 15.2 , Mann-Whitney U test, $p>0.05$; men vs. women at 52 weeks: 42.2 ± 16.4 vs. 42.1 ± 18.7 ; Mann-Whitney U test, $p>0.05$). In the longitudinal analysis using a linear mixed-effects model, there was a significant effect of time (Estimate = 9.911, SE = 1.276, $t=7.768$, $p<0.05$), a non-significant effect of gender (Estimate = 2.660, SE = 2.600, $t=1.023$, $p>0.05$), and a non-significant interaction between time and gender (Estimate = -2.578, SE = 1.869, $t=-1.380$, $p>0.05$).

The severity of motor symptoms and their impact on daily activities were comparable between men and

Table 1. Distribution of PSP phenotypes in male and female patients (n = 241).

	PSP-RS	PSP-OM	PSP-PI	PSP-P	PSP-F	PSP-PGF
Men (n = 134)	98 (73.1%)	2 (1.2%)	1 (0.8%)	26 (19.4%)	2 (1.5%)	5 (3.7%)
Women (n = 107)	85 (79.4%)	4 (3.7%)	2 (1.9%)	12 (11.2%)	1 (0.9%)	3 (2.8%)

The Fisher test was employed for the comparison between genders ($p > 0.05$). F: frontal lobe cognitive or behavioral presentations; OM: ocular motor dysfunction; P: Parkinsonism resembling idiopathic Parkinson's disease; PGF: progressive gait freezing; PI: postural instability; PSP: Progressive Supranuclear Palsy; RS: Richardson-Syndrome.

Table 2. Male and female PSP patient (n = 348) characteristics at baseline and annualized progression.

test time point	men		women	
	baseline	52-Week	baseline	52-Week
number of subjects	191	81	157	70
height (cm)	176.2 ± 6.9	—	163.8 ± 5.9*	—
body weight (kg)	83.0 ± 11.5	—	67.3 ± 12.2*	—
BMI (kg/m ²)	26.6 ± 3.1	—	25.1 ± 4.4*	—
age of the onset (years)	66.9 ± 7.8	—	65.8 ± 7.9	—
baseline age (years)	70.3 ± 7.2	—	69.2 ± 8.1	—
MoCA	19.3 ± 8.3	17.9 ± 9.3	19.5 ± 7.9	16.5 ± 10.2
Luria Sequence	1.7 ± 1.2	1.4 ± 1.3	1.4 ± 1.3	1.4 ± 1.3
three claps test	2.5 ± 0.8	2.3 ± 1.0	2.3 ± 0.9	2.3 ± 1.1
PSPRS	34.3 ± 14.8	42.2 ± 16.4 [#]	36.2 ± 15.2	42.1 ± 18.7 [#]
PSP-QoL	35.1 ± 19.1	38.4 ± 23.2	34.7 ± 20.6	39.4 ± 26.4
PSP-CDS	7.5 ± 3.8	8.8 ± 4.5 [#]	8.0 ± 3.9	8.8 ± 4.5
SSAS	16.9 ± 9.8	17.6 ± 11.2	14.5 ± 9.6*	12.5 ± 11.0*
GDS-15	5.8 ± 4.2	5.5 ± 4.3	5.8 ± 4.1	6.3 ± 5.1

Data is presented as mean ± standard deviation. The unpaired t-test for numerical values with a normal distribution and the Mann-Whitney U test for numerical values without a normal distribution were used. [#] $p < 0.05$ when comparing values obtained at the baseline visit with those obtained at the 52-week visit. * $p < 0.05$ when comparing values derived from men to those derived from women. BMI: body mass index; GDS-15: Geriatric Depression Scale-15 items; MoCA: The Montreal Cognitive Assessment; PSP-CDS: Progressive Supranuclear Palsy Clinical Deficits Scale; PSP-QoL: Progressive Supranuclear Palsy Quality of Life Scale; PSPRS: Progressive Supranuclear Palsy Rating Scale; SSAS: The Starkstein Apathy Scale.

women, showing similar baseline PSP-CDS scores (men: 7.5 ± 3.8 , women: 8.0 ± 3.9 ; Mann-Whitney U test, $p > 0.05$). This similarity persisted after 52 weeks (men: 8.8 ± 4.5 , women: 8.8 ± 4.5 ; Mann-Whitney U test, $p > 0.05$). Additionally, PSP-QoL scores were also comparable at baseline (men: 35.1 ± 19.1 , women: 34.7 ± 20.6 ; Mann-Whitney U test, $p > 0.05$) and after 52 weeks (men: 38.4 ± 23.2 , women: 39.4 ± 26.4 ; Mann-Whitney U test, $p > 0.05$). Moreover, no differences were observed in depressive symptoms assessed by GDS-15 between men and women with PSP at baseline (5.8 ± 4.2 vs. 5.8 ± 4.1 ; Mann-Whitney U test, $p > 0.05$) as well as at the 52-week follow-up (men vs. women: 5.5 ± 4.3 vs. 6.3 ± 5.1 ; Mann-Whitney U test, $p > 0.05$). The linear mixed-effects model revealed no statistically significant effects of time ($p > 0.05$), gender ($p > 0.05$), or their interaction ($p > 0.05$) on the scores of MoCA, Luria Sequence, three claps test, PSPRS, PSP-QoL, PSP-CDS and

GDS-15. This suggests that there were no significant longitudinal changes in these scores between men and women over one year.

However, male PSP patients showed significantly higher SSAS scores already at baseline, i.e., more apathy than women (men vs. women: 16.9 ± 9.8 vs. 14.5 ± 9.6 , Mann-Whitney U test, $p < 0.05$). This difference increased after a 52-week follow-up period (men vs. women: 17.6 ± 11.2 vs. 12.5 ± 11.0 , Mann-Whitney U test, $p < 0.05$). In the linear model analysis, there was a significant intercept (Estimate = 16.9172, SE = 0.8125, $t = 20.822$, $p < 0.05$) and a significant effect of gender (Estimate = -2.4598, SE = 1.2098, $t = -2.033$, $p < 0.05$), while the effects of time (Estimate = 0.7192, SE = 1.4935, $t = 0.482$, $p > 0.05$) and the interaction between time and gender (Estimate = -2.6604, SE = 2.1692, $t = -1.226$, $p > 0.05$) were non-significant. These results suggested a consistent gender-related disparity in apathy symptoms among PSP patients.

Discussion

In summary, the present study analyzed a large cohort of PSP patients ($n = 348$) for gender related aspects. The findings revealed only minor gender-specific differences among male and female PSP patients. The ratio of male to female in PSP patients is generally considered to be 1:1. In our study, a slightly higher proportion of male participants was observed. Consistent with national physical attribute data from Germany, men displayed significantly higher values in height, body weight, and body mass index. No differences were found in executive functions, motor control, disease severity, or daily living abilities between men and women. Consistent with a previous report,³ no difference in global cognitive status was observed between genders. Although it has been reported that women generally suffer more often from depressed mood and depression than men,¹⁰ we did not find the gender disparity in depression in PSP patients.

Notably, male patients with PSP present more apathy. Actually there are multiple factors that could complicate the assessment of apathy, such as bradykinesia and depression, which might interfere with the assessment of apathy. However, the SSAS is a validated 14-item questionnaire designed to assess apathy. It contains aspects such as learning, general interest, engagement, and goal-directed behavior, many of which help differentiate apathy from akinesia, although certain items (e.g., items 8, 12, and 14) may be influenced by factors affecting overall energy levels. Moreover, similar gender differences in apathy were also shown in studies of Parkinson's disease,^{11,12} Alzheimer's disease,¹³ vascular dementia¹⁴ and multiple sclerosis.¹⁵ The greater severity of apathy in men across various neurological disorders suggests that this phenomenon may not be disease-specific but rather gender-related. Understanding these gender differences can facilitate clinical trials, for example, when recruiting participants. Further studies should concentrate on gender differences in treatment response in patients with PSP.

As limitations, dropout occurred during our study follow-up, which is typical and almost unavoidable in a PSP observational cohort because of the severity of the disease. Additionally, we did not conduct extended neuropsychological assessments, such as Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Plus, and no imaging data were available for this analysis.

Acknowledgments

We would like to thank our patients and research volunteers.

ORCID iDs

Lan Ye  <https://orcid.org/0000-0002-3508-7359>

Ida Wilkens  <https://orcid.org/0009-0006-0270-0029>

Matthias Höllerhage  <https://orcid.org/0000-0002-5333-0121>

Monika Pötter-Nerger  <https://orcid.org/0000-0001-7680-2147>

Molly Zeitzschel  <https://orcid.org/0009-0001-1175-177X>
 Keno Hagen  <https://orcid.org/0009-0003-3024-0689>
 Jan Kassubek  <https://orcid.org/0000-0002-7106-9270>
 Daniela Berg  <https://orcid.org/0000-0001-5796-5442>
 Steffen Paschen  <https://orcid.org/0000-0002-9306-8332>
 Doreen Gruber  <https://orcid.org/0009-0009-4335-4718>
 Florin Gandor  <https://orcid.org/0000-0003-2874-9817>
 David J Pedrosa  <https://orcid.org/0000-0002-5403-1959>
 Claudia Trenkwalder  <https://orcid.org/0000-0001-6407-1199>
 Joseph Classen  <https://orcid.org/0000-0001-7182-6967>
 Alfons Schnitzler  <https://orcid.org/0000-0002-6414-7939>
 Günter U Höglinger  <https://orcid.org/0000-0001-7587-6187>
 Martin Klietz  <https://orcid.org/0000-0002-3054-9905>

Ethical considerations

We obtained approval of the local institutional review boards at Hannover Medical School and all participating study centers for this work (Ethics vote number: 3558-2017).

Consent to participate

All patients or legal caregivers gave their written informed consent.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability statement

The data supporting the findings of this study are available from the corresponding author Dr Lan Ye upon reasonable request.

References

1. Clayton JA and Tannenbaum C. Reporting sex, gender, or both in clinical research? *JAMA* 2016; 316: 1863–1864.
2. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. *Mov Disord* 2014; 29: 1758–1766.
3. Digma LA, Litvan I, Del Ser T, et al. Sex differences for cognitive decline in progressive supranuclear palsy. *Parkinsonism Relat Disord* 2023; 112: 105454.
4. Baba Y, Putzke JD, Whaley NR, et al. Progressive supranuclear palsy: phenotypic sex differences in a clinical cohort. *Mov Disord* 2006; 21: 689–692.
5. Mahale RR, Krishnan S, Divya KP, et al. Gender differences in progressive supranuclear palsy. *Acta Neurol Belg* 2022; 122: 357–362.
6. Gozes I, Shapira G, Lobyntseva A, et al. Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women. *Transl Psychiatry* 2023; 13: 319.

7. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord* 2017; 32: 853–864.
8. Piot I, Schweyer K, Respondek G, et al. The progressive supranuclear palsy clinical deficits scale. *Mov Disord* 2020; 35: 650–661.
9. Jensen I, Stiel S, Bebermeier S, et al. A short progressive supranuclear palsy quality of life scale. *Mov Disord* 2024; 39: 1602–1609.
10. Kuehner C. Why is depression more common among women than among men? *Lancet Psychiatry* 2017; 4: 146–158.
11. Pedersen KF, Alves G, Brønnick K, et al. Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. *J Neurol* 2010; 257: 217–223.
12. Meyer A, Zimmermann R, Gschwandtner U, et al. Apathy in Parkinson's disease is related to executive function, gender and age but not to depression. *Front Aging Neurosci* 2014; 6: 350.
13. Ott BR, Tate CA, Gordon NM, et al. Gender differences in the behavioral manifestations of Alzheimer's disease. *J Am Geriatr Soc* 1996; 44: 583–587.
14. Xing Y, Wei C, Chu C, et al. Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia. *Am J Alzheimers Dis Other Demen* 2012; 27: 433–438.
15. Novo AM, Batista S, Tenente J, et al. Apathy in multiple sclerosis: gender matters. *J Clin Neurosci* 2016; 33: 100–104.